Alvotech is a global biopharmaceutical company specializing in the development, manufacture and commercialization of high-quality biosimilar medicines. Founded in 2013 and headquartered in Reykjavík, Iceland, Alvotech aims to increase patient access to biologic therapies by offering more affordable versions of established biologic drugs. The company’s integrated model encompasses research and development, clinical testing, large-scale manufacturing and strategic partnerships, enabling it to bring biosimilars to market efficiently.
The company’s pipeline includes multiple monoclonal antibody and fusion protein candidates designed to mirror reference products used to treat autoimmune, inflammatory and ocular conditions, among others. Key programs include biosimilars of adalimumab (commonly prescribed for rheumatoid arthritis and plaque psoriasis) and bevacizumab (an anti-VEGF therapy for certain cancers), as well as follow-on versions of ranibizumab and ustekinumab. By focusing on high-barrier biologics with substantial global demand, Alvotech seeks to generate significant cost savings for healthcare systems and patients.
Alvotech operates a state-of-the-art manufacturing facility near Reykjavík, complemented by a European support site in Denmark and a commercial office in the United States. This geographic footprint allows the company to serve major markets in North America, Europe, Latin America and selected parts of Asia. Alvotech has entered into strategic licensing and distribution agreements with regional pharmaceutical partners to leverage established commercial networks and regulatory expertise, accelerating its global roll-out.
Under the leadership of founder and Executive Chairman Robert Wessman, a seasoned biotech entrepreneur with more than two decades of experience in life sciences, Alvotech has grown rapidly from a startup into a publicly traded company on the Nasdaq exchange. The leadership team combines veteran industry executives in R&D, quality control and commercial strategy, positioning Alvotech to navigate the complex biosimilar landscape and deliver on its mission of expanding patient access to critical biologic treatments.
AI Generated. May Contain Errors.
